EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
Volume 2.75M
Average 0.95M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -8.8% | +81.7% (5yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.8% over three years. Forward estimates point to Revenue at +81.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Kodiak Sciences Inc. NASDAQ:KOD | $5.39B | $85.75 | Not rated | -9.6 | +400.82% |
Tango Therapeutics, Inc. NASDAQ:TNGX | $3.72B | $22.04 | Not rated | -38.9 | +164.05% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $2.53B | $24.42 | Undervalued | -6.4 | -1.61% |
Septerna, Inc. NASDAQ:SEPN | $1.70B | $36.35 | Undervalued | -43.6 | +70.78% |
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX | $1.11B | $16.78 | Not rated | -8.8 | -38.21% |
Savara Inc. NASDAQ:SVRA | $914.30M | $4.45 | Not rated | -10.6 | +2.61% |
Kura Oncology, Inc. NASDAQ:KURA | $807.76M | $9.08 | Not rated | -2.9 | -35.16% |
Prime Medicine, Inc. NASDAQ:PRME | $629.38M | $3.47 | Not rated | -2.8 | +2.69% |
Rezolute, Inc. NASDAQ:RZLT | $346.27M | $3.58 | Not rated | -6.5 | -58.17% |
ProKidney Corp. NASDAQ:PROK | $197.06M | $1.33 | Not rated | -3.3 | -55.17% |
Continue the stock analysis
Jump to another research area for this company.